BRENNEN

Industries / Frontier science

Longevity

The longevity industry is the research and the companies working to slow aging itself and extend the years people live in good health.

1935

C. M. McCay, M. F. Crowell and L. A. Maynard reported in The Journal of Nutrition that rats fed fewer calories, but enough of every other nutrient, lived longer than rats that ate freely; a 2010 review in the same journal calls it the first demonstration that cutting calories alone lengthens life.

pmc.ncbi.nlm.nih.gov

41

Milestones achieved across 6 domains.

14

To watch for: announced, not yet confirmed outside.

12

Open deliverables. Nobody has shipped them.

In one minute

Where it started

In 1935 C. M. McCay and colleagues showed that rats fed fewer calories, but every other nutrient they needed, lived longer than rats that ate freely; almost 50 years passed before researchers took this up as a way to study aging. In 1961 L. Hayflick and P. S. Moorhead found that cultures of normal human cells die out after about 50 splits into fresh dishes, overturning the belief that cells grown outside the body do not age. Aging was still widely seen as too hard to study until worm genetics, from 1983 to 1993, showed that a change in one gene can lengthen life, through a growth signal later shown to do the same in flies and mice.

Where it stands

Researchers have found single genes that lengthen life in worms, flies and mice, and since 2013 have built clocks that estimate biological age from chemical marks on DNA, though repeat runs of one sample can differ by years unless a clock is built to resist the noise. The US National Institute on Aging's Interventions Testing Program tests compounds in mice at three sites; by April 2026 it had finished 99 test arms, and 34 lengthened life in at least one sex, among them rapamycin, acarbose and canagliflozin. No drug is approved to slow aging in people. A phase 3 trial of a rapamycin-like drug in older adults missed its goal in 2019, a drug meant to clear aged cells failed in arthritic knees in 2020, and a year-long rapamycin trial was null on its main measure in 2025. Meanwhile clinics sell scans, tests and infusions for cash; Abu Dhabi licensed its first longevity center in 2024, and Montana passed a law in 2025 to license experimental-treatment centers.

What is open

Most of what the field knows sits in papers, trial registries, clinic websites and regulators' letters, and little of it is gathered or checked. The open jobs below turn that material into public tables, forecasts and tests: which experiments behind the hallmarks of aging hold up, which reported young-blood factors have been confirmed, whether the software that computes aging clocks gives the same answer, which mouse tests will succeed, what registered aging trials measure, what clinics claim, and where each longevity substance may legally be sold. None needs a lab, a treatment or patient data.

Domains

AchievedWatch forOpen

Advances to build with

2 research notes

Open in longevity

3 of 12 open deliverables

Open · Biology of aging

Score the twelve hallmarks

A free, downloadable table with one row for each experiment that the 2023 hallmarks paper cites as evidence that a hallmark drives aging. Each row gives the hallmark; which of the paper's three tests it is cited for (appears with age, making it worse speeds aging, treating it slows aging); species and sex; whether lifespan was measured or only signs of health; the age at which the change began; whether young animals were tested as well as old; whether the animals had a disease-like shortened life; and whether a second, separate lab reported the same result. A summary page counts, for each hallmark, how many experiments meet each test.

Built with what exists

The 2023 paper's reference list from Crossref (294 of its 300 references carry a DOI), and the paper itself, free to read since January 2024 according to the licence in its Crossref record; the Europe PMC REST API for abstracts and open full texts; Keshavarz's spreadsheets as a template and as an answer key where the two papers cite the same studies; a large language model such as Claude to draft each row from the cited paper, with a person checking every field; a CSV file in a public GitHub repository. The Note "Findings that cite notes" covers an agent that cites the source behind each finding, the habit each row needs.

Credit · unclaimed

Open · Measuring age

Same clock, same number

A public test suite that feeds the same synthetic methylation data, made by computer with and without missing sites, to every open toolkit that implements a given clock, and publishes how far their answers differ, rerun on each new release.

Built with what exists

Biolearn and pyaging (Python); methylCIPHER, its rewrite methylCIPHERv2, and dnaMethyAge (R); methylclock (Bioconductor); OmniAge (R and Python, released July 2026); synthetic data from a fixed random seed; GitHub Actions to rerun the suite on each release.

Credit · unclaimed

Open · Drugs

Forecast the mouse tests

A public, time-stamped set of forecasts, from AI models and from people, of whether each ITP test arm still running will significantly extend median lifespan in male mice and in female mice, scored against the results as the ITP publishes them.

Built with what exists

The ITP results table and published papers as a base rate (34 of 99 finished arms showed a gain in at least one sex); DrugAge as background; language models that return a probability for each fixed-answer question, such as Gemini Decision 1 (see the Note "A thousand questions, one pass"); an Open Science Framework registration to fix the forecasts in time.

Credit · unclaimed